METXF
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, whic… Read more
METXF (METXF) - Total Liabilities
Latest total liabilities as of November 2025: $220.66K USD
Based on the latest financial reports, METXF (METXF) has total liabilities worth $220.66K USD as of November 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
METXF - Total Liabilities Trend (2022–2025)
This chart illustrates how METXF's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
METXF Competitors by Total Liabilities
The table below lists competitors of METXF ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Votum SA
WAR:VOT
|
Poland | zł263.24 Million |
|
Nebag ag
SW:NBEN
|
Switzerland | CHF42.11K |
|
Pruksa Holding Public Company Limited
BK:PSH
|
Thailand | ฿20.55 Billion |
|
Yuhwa Securities Co Ltd
KO:003465
|
Korea | ₩217.69 Billion |
|
Deutsch Motors Inc
KQ:067990
|
Korea | ₩1.30 Trillion |
|
Kyungdong Gas
KO:012320
|
Korea | ₩115.39 Billion |
|
Foseco India Limited
NSE:FOSECOIND
|
India | ₹1.52 Billion |
|
Medinice S.A
WAR:ICE
|
Poland | zł4.92 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down METXF's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how METXF's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for METXF (2022–2025)
The table below shows the annual total liabilities of METXF from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-08-31 | $256.27K | +307.30% |
| 2024-08-31 | $62.92K | -57.62% |
| 2023-08-31 | $148.47K | +319.77% |
| 2022-08-31 | $35.37K | -- |